Exelgyn

Mifepristone was originally developed by the French pharmaceutical company Roussel-Uclaf.

In 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997,{{cite news | vauthors = Moore SD, Kamm T, Fleming C |date=11 December 1996 |title=Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups |newspaper=The Wall Street Journal |page=A3}}
{{cite news | vauthors = Marshall M |date=11 December 1996 |title=Hoechst offers to pay $3.6 billion for rest of Roussel|newspaper=The Wall Street Journal |page=A8}}
{{cite news |agency=Bloomberg News |date=11 December 1996 |title=Hoechst to buy rest of Roussel |newspaper=The New York Times |page=D4 |url=https://www.nytimes.com/1996/12/11/business/hoechst-to-buy-rest-of-roussel.html |url-access=subscription |url-status=live |archive-url=https://web.archive.org/web/20160625124549/http://www.nytimes.com/1996/12/11/business/hoechst-to-buy-rest-of-roussel.html |archive-date=25 June 2016 }} Hoechst AG announced the end of its manufacture and sale of Mifegyne

1997, Exelgyn S.A. was founded, a single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz. Hoeschst AG transferred all rights for medical uses of mifepristone (outside of the United States) to Exelgyn.{{cite news|agency=Bloomberg News|date=9 April 1997|title=Pill for abortion ends production|newspaper=The New York Times|page=D2|url=https://www.nytimes.com/1997/04/09/business/pill-for-abortion-ends-production.html|url-status=live |url-access=subscription |archive-url=https://web.archive.org/web/20160625134359/http://www.nytimes.com/1997/04/09/business/pill-for-abortion-ends-production.html|archive-date=25 June 2016}}
{{cite news | vauthors = Jouzaitis C |date=9 April 1997 |title=Abortion pill maker bows to boycott heat; German firm gives up RU-486 patent; little impact likely in U.S. |newspaper=Chicago Tribune |page=4 |url=https://pqasb.pqarchiver.com/chicagotribune/access/11401570.html?dids=11401570:11401570&FMT=ABS&FMTS=ABS:FT |url-status=dead |archive-url=https://web.archive.org/web/20130218193350/http://pqasb.pqarchiver.com/chicagotribune/access/11401570.html?dids=11401570%3A11401570&FMT=ABS&FMTS=ABS%3AFT |archive-date=18 February 2013 }}
{{cite news | vauthors = Lavin D |date=9 April 1997 |title=Hoechst will stop making abortion pill |newspaper=The Wall Street Journal |page=A3}}
{{cite journal |date=18 April 1997 |title=Roussel-Uclaf to transfer RU 486 rights |journal=Reprod Freedom News |volume=6 |issue=7 |page=8 |pmid=12292550}}
{{cite journal | vauthors = Dorozynski A |date=19 April 1997 |title=Boycott threat forces French company to abandon RU486 |journal=BMJ |volume=314|issue=7088 |page=1150 |pmid=9146386 |pmc=2126515 |doi=10.1136/bmj.314.7088.1145m}}

In 1999, Exelgyn won approval of Mifegyne in 11 additional countries.{{cite web|date=4 November 2009|title=List of mifepristone approval|location=New York|publisher=Gynuity Health Projects|url=http://gynuity.org/downloads/mife_approval_2009_list.pdf|url-status=dead|archive-url=https://web.archive.org/web/20110726135110/http://gynuity.org/downloads/mife_approval_2009_list.pdf|archive-date=26 July 2011|access-date=4 May 2018}}
{{cite web|date=4 November 2009|title=Map of mifepristone approval|location=New York|publisher=Gynuity Health Projects|url=http://gynuity.org/downloads/Mife_approval_2009_map.pdf|access-date=11 June 2010|url-status=dead|archive-url=https://web.archive.org/web/20110726135136/http://gynuity.org/downloads/Mife_approval_2009_map.pdf|archive-date=26 July 2011}} As of 2024, Exelgyn distributes mifepristone to 40 countries,https://exelgyn.com/our-global-presence/ but within the United States it is distributed by Danco Laboratories and GenBioPro.

• {{official website|https://www.earlyoptionpill.com}}

Category:Pharmaceutical companies disestablished in 1997

Category:Pharmaceutical companies of France

Category:Abortion in France